Atazanavir-Associated QT Interval Prolongation and Torsades de Points in a Patient With Liver Cirrhosis
Authors:
- Devindra S. DabiesinghDDDevindra S. Dabiesingh
- George PsevdosGPGeorge Psevdos
- Victoria L. SharpVSVictoria L. Sharp
- 1 May 2011
- journal article
- Published by Wolters Kluwer Health in Infectious Diseases in Clinical Practice
- Vol. 19 (3) , 226-228
Abstract
No abstract availableThis publication has 13 references indexed in Scilit:
- HIV Protease Inhibitors Induced Prolongation of the QT Interval: Electrophysiology and Clinical ImplicationsAmerican Journal of Therapeutics, 2010
- Effects of Standard and Supratherapeutic Doses of Nelfinavir on Cardiac Repolarization: A Thorough QT StudyThe Journal of Clinical Pharmacology, 2009
- Relationship between HIV protease inhibitors and QTc interval duration in HIV‐infected patients: a cross‐sectional studyBritish Journal of Clinical Pharmacology, 2008
- Ritonavir‐Boosted Atazanavir, Methadone, and Ventricular Tachycardia: 2 Case ReportsClinical Infectious Diseases, 2008
- Ritonavir 100 mg Does Not Cause QTc Prolongation in Healthy Subjects: A Possible Role as CYP3A Inhibitor in Thorough QTc StudiesClinical Pharmacology & Therapeutics, 2007
- Prolonged QT Interval and Torsades de Pointes Associated with Atazanavir TherapyClinical Infectious Diseases, 2007
- Blockade of HERG channels by HIV protease inhibitorsThe Lancet, 2005
- Atazanavir: improving the HIV protease inhibitor classExpert Review of Anti-infective Therapy, 2003
- A practical approach to torsade de pointesClinical Cardiology, 1997
- Electrophysiologic Mechanisms of the Long QT Interval Syndromes and Torsade de PointesAnnals of Internal Medicine, 1995